Mira-Lynn Chavanon1,2,3, Simone Inkrot4, Christine Zelenak4, Elvis Tahirovic4,5, Dragana Stanojevic6, Svetlana Apostolovic6, Aleksandra Sljivic7,8, Arsen D Ristic8,9, Dragan Matic8,10, Goran Loncar8,11, Jovan Veskovic4,5, Marija Zdravkovic12, Mitja Lainscak13, Burkert Pieske4,5, Christoph Herrmann-Lingen14,15, Hans-Dirk Düngen4,5. 1. Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany. Chavanon@uni-marburg.de. 2. German Centre for Cardiovascular Research DZHK, Partner Site Göttingen, Göttingen, Germany. Chavanon@uni-marburg.de. 3. Department of Psychology, Philipps-Universität Marburg, Gutenbergstraße 18, 35032, Marburg, Germany. Chavanon@uni-marburg.de. 4. Department of Internal Medicine-Cardiology, Charité University Medicine Berlin, Berlin, Germany. 5. German Centre for Cardiovascular Research DZHK, Partner Site Berlin, Berlin, Germany. 6. Clinic for Cardiovascular Diseases, Clinical Centre Nis, University of Niš, Niš, Serbia. 7. Department of Cardiology, University Hospital Centre 'Dr Dragisa Misovic-Dedinje', Belgrade, Serbia. 8. School of Medicine, University of Belgrade, Belgrade, Serbia. 9. Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia. 10. Emergency Department, Clinical Center of Serbia, Belgrade, Serbia. 11. Department of Cardiology, Clinical Hospital Zvezdara, Belgrade, Serbia. 12. Department of Cardiology, University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia. 13. Department of Internal Medicine, General Hospital Murska Sobota and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. 14. Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany. 15. German Centre for Cardiovascular Research DZHK, Partner Site Göttingen, Göttingen, Germany.
Abstract
AIM: Patient-reported outcomes such as health-related quality of life (HRQoL) are main treatment goals for heart failure (HF) and therefore endpoints in multinational therapy trials. However, little is known about country-specific differences in HRQoL and in treatment-associated HRQoL improvement. The present work sought to examine those questions. METHODS AND RESULTS: We analysed data from the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trial, in which patients from central and south-eastern Europe completed the HRQoL questionnaire SF-36 at baseline and the end of a 12-week beta-blocker up-titration (follow-up). 416 patients from Serbia (mean age 72.21 years, 69% NYHA-class I-II, 27.4% women) and 114 from Germany (mean age 73.64 years, 78.9% NYHA-class I-II, 47.4% women) were included. Controlling for clinical variables, the change in mental HRQoL from baseline to follow-up was modulated by Country: Serbian patients, M baseline = 37.85 vs. M follow-up = 40.99, t(526) = 5.34, p < .001, reported a stronger increase than Germans, M baseline = 37.66 vs. M follow-up = 38.23, t(526) = 0.68, ns. For physical HRQoL, we observed a main effect of Country, M Serbia = 39.28 vs. M Germany = 35.29, t(526) = 4.24, p < .001. CONCLUSION: We observed significant differences in HF patients from Germany and Serbia and country-specific differences between Serbian and German patients in mean physical HRQoL. Changes in mental HRQoL were modulated by country. Those results may reflect psychological, sociocultural, aetiological differences or regional differences in phenotype prevalence. More importantly, they suggest that future multinational trials should consider such aspects when designing a trial in order to avoid uncertainties aligned to data interpretation and to improve subsequent treatment optimisation.
RCT Entities:
AIM: Patient-reported outcomes such as health-related quality of life (HRQoL) are main treatment goals for heart failure (HF) and therefore endpoints in multinational therapy trials. However, little is known about country-specific differences in HRQoL and in treatment-associated HRQoL improvement. The present work sought to examine those questions. METHODS AND RESULTS: We analysed data from the Cardiac InsufficiencyBisoprolol Study in Elderly (CIBIS-ELD) trial, in which patients from central and south-eastern Europe completed the HRQoL questionnaire SF-36 at baseline and the end of a 12-week beta-blocker up-titration (follow-up). 416 patients from Serbia (mean age 72.21 years, 69% NYHA-class I-II, 27.4% women) and 114 from Germany (mean age 73.64 years, 78.9% NYHA-class I-II, 47.4% women) were included. Controlling for clinical variables, the change in mental HRQoL from baseline to follow-up was modulated by Country: Serbian patients, M baseline = 37.85 vs. M follow-up = 40.99, t(526) = 5.34, p < .001, reported a stronger increase than Germans, M baseline = 37.66 vs. M follow-up = 38.23, t(526) = 0.68, ns. For physical HRQoL, we observed a main effect of Country, M Serbia = 39.28 vs. M Germany = 35.29, t(526) = 4.24, p < .001. CONCLUSION: We observed significant differences in HF patients from Germany and Serbia and country-specific differences between Serbian and German patients in mean physical HRQoL. Changes in mental HRQoL were modulated by country. Those results may reflect psychological, sociocultural, aetiological differences or regional differences in phenotype prevalence. More importantly, they suggest that future multinational trials should consider such aspects when designing a trial in order to avoid uncertainties aligned to data interpretation and to improve subsequent treatment optimisation.
Entities:
Keywords:
Beta-blocker; Heart failure; Patient-reported outcomes; Quality of life
Authors: Imke H Kraai; Karin M Vermeulen; Marie Louise A Luttik; Tialda Hoekstra; Tiny Jaarsma; Hans L Hillege Journal: Eur J Heart Fail Date: 2013-05-05 Impact factor: 15.534
Authors: K Mulligan; P A Mehta; T Fteropoulli; S W Dubrey; H F McIntyre; T A McDonagh; G C Sutton; D M Walker; M R Cowie; S Newman Journal: Br J Health Psychol Date: 2011-08-25
Authors: Debra K Moser; Seongkum Heo; Kyoung Suk Lee; Muna Hammash; Barbara Riegel; Terry A Lennie; Cynthia Arslanian-Engoren; Gia Mudd-Martin; Nancy Albert; John Watkins Journal: Age Ageing Date: 2013-07-05 Impact factor: 10.668